Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma

Liver International

Volumn 35, Issue 3, 2015, Pages 1063-1076

  Mohamed, Fatma E ^a,b   Al Jehani, Rajai M ^c   Minogue, Shane S ^a   Andreola, Fausto ^a   Winstanley, Alison ^d   Olde Damink, Steven W M ^a   Habtesion, Abeba ^a   Malagó, Massimo ^a   Davies, Nathan ^a   Luong, Tu Vinh ^c   Dhillon, Amar P ^c   Mookerjee, Rajeshwar P ^a   Dhar, Dipok K ^a   Jalan, Rajiv ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b MINIA UNIVERSITY   (Egypt)

^c ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

AKT; Chloroquine; CpG ODN; DEN NMOR; HCC; Imiquimod; IRS; NF kB; TLR; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; CHLOROQUINE; CPG OLIGODEOXYNUCLEOTIDE; DIETHYLNITROSAMINE; IMIQUIMOD; IRS 954; NITROSOMORPHOLINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; PROTEIN KINASE B; VASCULOTROPIN A;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; TUMOR XENOGRAFT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; DRUG EFFECTS; DRUG SCREENING; FISCHER 344 RAT; HEPG2 CELL LINE; LIVER; LIVER NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; NONOBESE DIABETIC MOUSE; RANDOMIZATION; SCID MOUSE; TISSUE MICROARRAY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL PROLIFERATION; CHLOROQUINE; DNA; HEP G2 CELLS; HUMANS; KI-67 ANTIGEN; LIVER; LIVER NEOPLASMS; MICE, INBRED NOD; MICE, SCID; MOLECULAR TARGETED THERAPY; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; RATS, INBRED F344; TISSUE ARRAY ANALYSIS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922688857     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12626     Document Type: Article

References (56)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: globocan 2000. Int J Cancer 2001; 94: 153-6.
2. Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797-803.
3. Sherman M. Surveillance of hepatocellular carcinoma: we must do better. Am J Med 2008; 121: 89-90.
4. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92.
5. Fung J, Lai CL, Yuen MF. Hepatitis B and C virus-related carcinogenesis. Clin Microbiol Infect 2009; 15: 964-70.
6. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
7. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
8. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48: 322-35.
9. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-85.
10. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
11. Nishikori M. Classical and alternative NF-κB activation pathways and their roles in lymphoid malignancies. J Clin Exp Hematopathol 2005; 45: 10.
12. Takeda K, Akira S. Microbial recognition by Toll-like receptors. J Dermatol Sci 2004; 34: 73-82.
13. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13: 816-25.
14. Choi JH, Yang YR, Lee SK, et al. Potential inhibition of PDK1/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival. Ann N Y Acad Sci 2008; 1138: 393-403.
15. Guiducci C, Ghirelli C, Marloie-Provost MA, et al. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med 2008; 205: 315-22.
16. Firat E, Weyerbrock A, Gaedicke S, et al. Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote γ-irradiation-induced cell death in primary stem-like glioma cells. PLoS ONE 2012; 7: e47357.
17. Chang YJ, Wu MS, Lin JT, et al. Helicobacter pylori-Induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 2005; 175: 8242-52.
18. Sato T, Yamamoto M, Shimosato T, et al. Accelerated wound healing mediated by activation of Toll-like receptor 9. Wound Repair Regen 2010; 18: 586-93.
19. Li WW, Talcott KE, Zhai AW. Imiquimod as an antiangiogenic agent. J Drugs Dermatol 2005; 4: 708-17.
20. Majewski S, Marczak M, Mlynarczyk B, et al. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 2005; 44: 14-9.
21. Damiano V, Caputo R, Bianco R, et al. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 2006; 12: 577-83.
22. Seki E, Park E, Fujimoto J. Toll-like receptor signaling in liver regeneration, fibrosis and carcinogenesis. Hepatol Res 2011; 41: 597-610.
23. Gabele E, Muhlbauer M, Dorn C, et al. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun 2008; 376: 271-6.
24. Stadlbauer V, Mookerjee RP, Wright GA, et al. Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G15-22.
25. Platta HW, Stenmark H. Endocytosis and signaling. Curr Opin Cell Biol 2011; 23: 393-403.
26. Polo S, Pece S, Di Fiore PP. Endocytosis and cancer. Curr Opin Cell Biol 2004; 16: 156-61.
27. Huang B, Zhao J, Unkeless JC, et al. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008; 27: 218-24.
28. Wolska A, Cebula-Obrzut B, Smolewski P, et al. Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine. Leuk Lymphoma 2013; 54: 1268-78.
29. Droemann D, Albrecht D, Gerdes J, et al. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 2005; 6: 1.
30. Schmausser B, Andrulis M, Endrich S, et al. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 2005; 295: 179-85.
31. Lee JW, Choi JJ, Seo ES, et al. Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog 2007; 46: 941-7.
32. Ilvesaro JM, Merrell MA, Swain TM, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007; 67: 774-81.
33. Ochi A, Graffeo CS, Zambirinis CP, et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest 2012; 122: 4118-29.
34. Sun S, Rao NL, Venable J, et al. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 2007; 6: 223-35.
35. Ohkuma S, Poole B. Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances. J Cell Biol 1981; 90: 656-64.
36. Brown ND, Stermer-Cox MG, Poon BT, et al. Separation and identification of a plasma and urinary mono-acetylated conjugate of chloroquine in man by ion-pair high-performance liquid chromatography. J Chromatogr 1984; 309: 426-30.
37. Ding ZB, Hui B, Shi YH, et al. Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation. Clin Cancer Res 2011; 17: 6229-38.
38. Al-Sader MH, Doyle E, Kay EW, et al. Proliferation indexes-a comparison between cutaneous basal and squamous cell carcinomas. J Clin Pathol 1996; 49: 549-51.
39. Minogue S, Waugh MG, De Matteis MA, et al. Phosphatidylinositol 4-kinase is required for endosomal trafficking and degradation of the EGF receptor. J Cell Sci 2006; 119: 571-81.
40. Scatton O, Chiappini F, Riou P, et al. Fate and characterization of circulating tumor cells in a NOD/SCID mouse model of human hepatocellular carcinoma. Oncogene 2006; 25: 4067-75.
41. Yoshino H, Futakuchi M, Cho YM, et al. Modification of an in vivo lung metastasis model of hepatocellular carcinoma by low dose N-nitrosomorpholine and diethylnitrosamine. Clin Exp Metastasis 2005; 22: 441-7.
42. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 2009; 58: 704-20.
43. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-32.
44. Tanaka J, Sugimoto K, Shiraki K, et al. Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas. Int J Oncol 2010; 37: 805-14.
45. Cherfils-Vicini J, Platonova S, Gillard M, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010; 120: 1285-97.
46. Sheyhidin I, Nabi G, Hasim A, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17: 3745-51.
47. Min R, Zun Z, Siyi L, et al. Increased expression of Toll-like receptor-9 has close relation with tumour cell proliferation in oral squamous cell carcinoma. Arch Oral Biol 2011; 56: 877-84.
48. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 2009; 14: 248-72.
49. Schmidt C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 2007; 25: 825-6.
50. Fan C, Wang W, Zhao B, et al. Chloroquine inhibits cell growth and induces cell death in A549 lung cancer cells. Bioorg Med Chem 2006; 14: 3218-22.
51. Zheng Y, Zhao YL, Deng X, et al. Chloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis. Cancer Invest 2009; 27: 286-92.
52. Yasuda H, Leelahavanichkul A, Tsunoda S, et al. Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol 2008; 294: F1050-8.
53. Rutz M, Metzger J, Gellert T, et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 2004; 34: 2541-50.
54. Ramser B, Kokot A, Metze D, et al. Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts. J Invest Dermatol 2009; 129: 2419-26.
55. Janku F, McConkey DJ, Hong DS, et al. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 2011; 8: 528-39.
56. Kawai T, Akira S. Innate TLR signaling. Cell Death Differ 2006; 13: 816-25.